 |
|
Ivan Marazzi, PhD The Department of Biological Chemistry, UCI School of Medicine
professor in the Department of Biological
Ivan Marazzi, PhD Chemistry, has been appointed as director of the Center for Epigenetics & Metabolism (CEM), effective July 1, 2023.
Dr. Marazzi’s appointment comes after the leader, inaugural director and founder of the UCI Center for Epigenetics & Metabolism, Dr. Sassone-Corsi, passed away in 2020. Dr. Marazzi will build on the international recognition of the CEM as a center of excellence in the areas of epigenetic and metabolism research.
Currently comprising 27 diverse faculty members and securing over 40 NIH grants totaling more than $20 million annually, the CEM thrives on collaborative and interdisciplinary research. Its members are committed to unraveling the intricate molecular mechanisms through which genetics, the environment and lifestyle influence human health.
In assuming this new role, Dr. Marazzi will foster continued collaboration between the CEM and the UCI Health Chao Family Comprehensive Cancer Center. Furthermore, he aims to expand partnerships with groups specializing in neurological and metabolic disease research. By synergizing efforts across these domains, Dr. Marazzi intends to grow an environment that drives transformative advances.
Dr. Marazzi received his bachelor’s degree in molecular virology from the University Pavia, Italy. He received his doctorate in immunology and biochemistry at the I.R.B. Institute Bellinzona and the University of Freiburg, Switzerland. Then, in 2006, he joined Rockefeller University, New York, for postdoctoral research in the area of epigenetics. Dr. Marazzi was recruited to the Icahn School of Medicine New York as an assistant professor in 2013, and he joined UCI in 2022 as a professor in the Department of Biological Chemistry.
Dr. Marazzi has a broad background in virology, immunology, molecular biology, biochemistry, genetics and epigenetics. His group uses a combination of these disciplines and chemical biology to characterize and control gene regulatory networks, and to understand how disruptions of these networks by genetic and epigenetic changes can lead to disease.
Ivan Marazzi, PhD Chemistry, has been appointed as director of the Center for Epigenetics & Metabolism (CEM), effective July 1, 2023.
Dr. Marazzi’s appointment comes after the leader, inaugural director and founder of the UCI Center for Epigenetics & Metabolism, Dr. Sassone-Corsi, passed away in 2020. Dr. Marazzi will build on the international recognition of the CEM as a center of excellence in the areas of epigenetic and metabolism research.
Currently comprising 27 diverse faculty members and securing over 40 NIH grants totaling more than $20 million annually, the CEM thrives on collaborative and interdisciplinary research. Its members are committed to unraveling the intricate molecular mechanisms through which genetics, the environment and lifestyle influence human health.
In assuming this new role, Dr. Marazzi will foster continued collaboration between the CEM and the UCI Health Chao Family Comprehensive Cancer Center. Furthermore, he aims to expand partnerships with groups specializing in neurological and metabolic disease research. By synergizing efforts across these domains, Dr. Marazzi intends to grow an environment that drives transformative advances.
Dr. Marazzi received his bachelor’s degree in molecular virology from the University Pavia, Italy. He received his doctorate in immunology and biochemistry at the I.R.B. Institute Bellinzona and the University of Freiburg, Switzerland. Then, in 2006, he joined Rockefeller University, New York, for postdoctoral research in the area of epigenetics. Dr. Marazzi was recruited to the Icahn School of Medicine New York as an assistant professor in 2013, and he joined UCI in 2022 as a professor in the Department of Biological Chemistry.
Dr. Marazzi has a broad background in virology, immunology, molecular biology, biochemistry, genetics and epigenetics. His group uses a combination of these disciplines and chemical biology to characterize and control gene regulatory networks, and to understand how disruptions of these networks by genetic and epigenetic changes can lead to disease.
Over the course of his career, his group published several seminal studies that led to molecular understanding of disease and resulted in clinical trials and several patents for novel treatment of infectious, inflammatory and neurodegenerative diseases. His research is funded by multiple grants and program projects from the NIH, as well as awards from the Chan Zuckerberg Initiative and the Burrough Wellcome Fund.